Rheumatoid Arthritis Clinical Studies

You have full text access to this OnlineOpen article

Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies†

  1. S. A. Saunders1,‡,*,
  2. H. A. Capell2,
  3. A. Stirling1,
  4. R. Vallance1,
  5. W. Kincaid1,
  6. A. D. McMahon3,
  7. D. R. Porter1,‡

Article first published online: 25 APR 2008

DOI: 10.1002/art.23449

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 58, Issue 5, pages 1310–1317, May 2008

Additional Information

How to Cite

Saunders, S. A., Capell, H. A., Stirling, A., Vallance, R., Kincaid, W., McMahon, A. D. and Porter, D. R. (2008), Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis & Rheumatism, 58: 1310–1317. doi: 10.1002/art.23449

Author Information

  1. 1

    Gartnavel General Hospital, Glasgow, UK

  2. 2

    Glasgow Royal Infirmary, Glasgow, UK

  3. 3

    University of Glasgow, Glasgow, UK

  1. ‡

    Dr. Saunders has received speaking fees (less than $10,000 each) from Wyeth, Merck, Sharp, & Dohme. Dr. Porter has received consulting and speaking fees (less than $10,000 each) from Abbott, Roche, and Bristol-Myers Squibb, and consulting fees (less than $10,000) from Wyeth.

*Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK

  1. †

    EudraCT database no. 2004-002006-30.

Publication History

  1. Issue published online: 25 APR 2008
  2. Article first published online: 25 APR 2008
  3. Manuscript Accepted: 1 FEB 2008
  4. Manuscript Received: 24 JUL 2007

Funded by

  • Chief Scientist Office of the Scottish Executive

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (167K)

REFERENCES

  • 1
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91.
  • 2
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164–70.
    Direct Link:
  • 3
    Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, for the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568–73.
  • 4
    Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published erratum appears in Lancet 1998;351:220]. Lancet 1997; 350: 309–18.
  • 5
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263–9.
  • 6
    Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916–20.
  • 7
    Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 8
    Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994; 41: 86–9.
  • 9
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 10
    Ware JE, Kosinski M, Keller SD. A 12-item Short Form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–33.
  • 11
    Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261–3]. J Rheumatol 1999; 26: 743–5.
  • 12
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:76,240]. N Engl J Med 2000; 343: 1586–93.
  • 13
    St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43.
    Direct Link:
  • 14
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
    Direct Link:
  • 15
    Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al, for the FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study group. Arthritis Rheum 2004; 50: 2072–81.
    Direct Link:
  • 16
    Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36–41.
    Direct Link:
  • 17
    Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347–56.
    Direct Link:
  • 18
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381–90.
    Direct Link:
  • 19
    Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006; 54: 3119–25.
    Direct Link:
  • 20
    Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 1999; 58: 510–3.
View Full Article (HTML) Get PDF (167K)